Evaluation of the Presence and Effects of Kinesiophobia in Multiple Sclerosis

NCT06167447 | Completed

• 1 other identifier: BNKilinc
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study was to evaluate the presence of kinesiophobia in multiple sclerosis and to investigate the effect of kinesiophobia on physical activity, functional status, quality of life and depression.

Conditions

Multiple Sclerosis; Kinesiophobia

Keywords

Multiple sclerosis; kinesiophobia; fear of movement

Outcome Measures

Primary Outcomes (1)

• Tampa Scale of Kinesiophobia

  Tampa Scale of Kinesiophobia is a checklist of 17 questions developed to measure the fear of movement and re-injury. It is used in many situations such as Acute and chronic pain, Fibromyalgia Syndrome (FMS), musculoskeletal system related injuries, etc. Items in the scale are scored according to a 4-point Likert scoring. A total score of 37 points and above indicates a high level of kinesiophobia.

  through study completion, an average of 6 months.

Study Arms (2)

multiple sclerosis group

Demographic data of all participants were recorded. Tampa Scale of Kinesiophobia (TSK), Beck Depression Inventory (BDI), Quality of Life Scale Short Form-36 (SF-36), International Physical Activity Questionnaire Short Form (IPAQ-SF), Functional Ambulation Classification (FAS), Functional Independence Measure (FIM), Expanded Disability Status Scale (EDSS) were implemented.

Other: questionnaire and examination

control group

Demographic data of all participants were recorded. Tampa Scale of Kinesiophobia (TSK), Beck Depression Inventory (BDI), Quality of Life Scale Short Form-36 (SF-36), International Physical Activity Questionnaire Short Form (IPAQ-SF), Functional Ambulation Classification (FAS)

Other: questionnaire and examination

Interventions

questionnaire and examination OTHER

Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.

control group; multiple sclerosis group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

A total of 90 people, 45 patients and 45 healthy controls, who applied to the Gazi University Medical School PM\&R and Neurology multiple sclerosis outpatient clinic between the ages of 18-65, were included in the study.

You may qualify if:

• Having a definitive diagnosis of MS according to the 2017 Revised McDonald Diagnostic Criteria
• Expanded Disability Status Scale (EDSS) score between 0-6.5
• Be between the ages of 18-65
• Volunteering to participate in the study

You may not qualify if:

• Having orthopedic, psychiatric and other chronic diseases other than MS that may affect physical and cognitive status
• Expanded Disability Status Scale (EDSS) score \>6.5
• Being in the MS attack period

Sponsors & Collaborators

• Gazi University: lead

Study Sites (1)

Bilge Nur Kılınç

Ankara, 06550, Turkey (Türkiye)

Location

Related Publications (4)

• Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019 Jan;26(1):27-40. doi: 10.1111/ene.13819. Epub 2018 Nov 18.

  PMID: 30300457 BACKGROUND

• Zalc B. One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological disease. Brain. 2018 Dec 1;141(12):3482-3488. doi: 10.1093/brain/awy287. No abstract available.

  PMID: 30462211 BACKGROUND

• Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816-1821. doi: 10.1177/1352458520970841. Epub 2020 Nov 11.

  PMID: 33174475 BACKGROUND

• Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 2005 Oct;4(10):643-52. doi: 10.1016/S1474-4422(05)70193-9.

  PMID: 16168933 BACKGROUND

MeSH Terms

Conditions

Multiple Sclerosis; Kinesiophobia

Interventions

Surveys and Questionnaires; Restraint, Physical

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Phobic Disorders; Anxiety Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health; Behavior Control; Therapeutics; Immobilization

Study Officials

• Bilge Nur Kilinc

  Gazi University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 26, 2023
• First Posted: December 12, 2023
• Study Start: January 1, 2021
• Primary Completion: May 1, 2021
• Study Completion: June 30, 2021
• Last Updated: December 12, 2023

Record last verified: 2023-12

Locations

TU (1)